{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:15:27Z","timestamp":1788372927918,"version":"build-2803163510"},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hearing the Ovarian Cancer Whisper Jacquie Liggett Fellowship"},{"name":"Sarasota foundation fund"},{"name":"National Institutes of Health, National Cancer Institute","award":["R21 CA252373"],"award-info":[{"award-number":["R21 CA252373"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Cancer Center Support Grant :P30-CA076292"],"award-info":[{"award-number":["Cancer Center Support Grant :P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health, National Cancer Institute","award":["R21 CA252373"],"award-info":[{"award-number":["R21 CA252373"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Ovarian cancer remains a leading cause of gynecologic cancer\u2013related deaths worldwide. Deficiencies in BRCA1\/2 are well-established biomarkers that predict sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPis). However, emerging evidence indicates that a subset of\n                    <jats:italic>BRCA<\/jats:italic>\n                    -proficient tumors also responds to PARPi therapy, suggesting the presence of additional molecular mechanisms. We hypothesized that the composition of the PARP1 protein complex and PARylation-mediated signaling contribute to PARPi response in\n                    <jats:italic>BRCA<\/jats:italic>\n                    -proficient HGSOC. We assessed PARPi response across a panel of\n                    <jats:italic>BRCA<\/jats:italic>\n                    -proficient ovarian cancer cell lines and identified distinct sensitive and resistant groups. Chemical proteomics with rucaparib revealed different PARP1 complexes including higher enrichment of MSH6 in sensitive cells. Co-immunoprecipitation analyses further confirmed differential assembly of PARP1\u2013MSH6\u2013PARP2 complexes between sensitive and resistant models. To explore PARylation signaling, we performed ADP-ribosylation proteomics using clickable NAD\u207a analogs, revealing distinct PARylation profiles between sensitive and resistant cell lines. CHAF1A, a known MSH6 interactor and PARP1 substrate, showed more pronounced reduction in ADP-ribosylation in PARPi-sensitive cells. Targeting\n                    <jats:italic>MSH6<\/jats:italic>\n                    using CRISPR or siRNA decreased PARPi sensitivity. In addition, mTOR signaling was reduced in sensitive, but increased in resistant cells, following rucaparib treatment. Notably,\n                    <jats:italic>MSH6<\/jats:italic>\n                    knockdown led to increased CHAF1A expression regardless of rucaparib treatment. Importantly, knockdown of\n                    <jats:italic>CHAF1A<\/jats:italic>\n                    significantly impaired cell viability, especially in A2780 cells, and suppressed mTOR signaling, suggesting that CHAF1A acts downstream of MSH6 to regulate the mTOR axis. Furthermore, co-treatment with mTORC1 inhibitors enhanced the cellular effects of rucaparib in resistant cells, suggesting a therapeutic potential of targeting downstream mTOR effectors to overcome intrinsic resistance. In conclusion, this study identifies the PARP1\u2013MSH6 interaction to modulate PARPi sensitivity via CHAF1A-mTOR signaling in\n                    <jats:italic>BRCA<\/jats:italic>\n                    -proficient ovarian cancer. By integrating chemical proteomics and ADP-ribosylation proteomics, we delineate the interplay between PARP1 complex composition and signaling dynamics, highlighting MSH6 as a critical modulator of PARPi response and potential biomarker to enhance therapeutic efficacy in\n                    <jats:italic>BRCA<\/jats:italic>\n                    -proficient HGSOC.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0357365","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:35:11Z","timestamp":1788370511000},"page":"e0357365","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1\/2-proficient ovarian cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9933-1832","authenticated-orcid":true,"given":"Ou","family":"Deng","sequence":"first","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"],"department":["Department of Drug Discovery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales Da Costa","family":"Nepomuceno","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"],"department":["Department of Cancer Epidemiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fang","sequence":"additional","affiliation":[{"name":"Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Welsh","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Izumi","sequence":"additional","affiliation":[{"name":"Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael H.","family":"Martin","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"],"department":["Department of Cancer Epidemiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"George","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute","place":["Tampa, Florida, United States of America"],"department":["Department of Gynecologic Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-1762","authenticated-orcid":true,"given":"John M.","family":"Koomen","sequence":"additional","affiliation":[{"name":"Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"]},{"name":"University of South Florida","place":["Tampa, Florida, United States of America"],"department":["Department of Molecular Biosciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro N.","family":"Monteiro","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"],"department":["Department of Cancer Epidemiology"]},{"name":"University of South Florida","place":["Tampa, Florida, United States of America"],"department":["Department of Molecular Biosciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Rix","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, Florida, United States of America"],"department":["Department of Drug Discovery"]},{"name":"University of South Florida","place":["Tampa, Florida, United States of America"],"department":["Department of Molecular Biosciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"1","key":"pone.0357365.ref001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"RL Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"pone.0357365.ref002","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2025.2873","article-title":"Personalized Primary and Secondary Prevention in Ovarian Cancer","volume":"11","author":"M Widschwendter","year":"2025","journal-title":"JAMA Oncol"},{"key":"pone.0357365.ref003","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251332441","article-title":"The Role of GPX1 (rs1050450) Variants in Ovarian Cancer Susceptibility Within a Turkish Population","volume":"32","author":"B Alsheikh","year":"2025","journal-title":"Cancer Control"},{"issue":"6330","key":"pone.0357365.ref004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"CJ Lord","year":"2017","journal-title":"Science"},{"issue":"26","key":"pone.0357365.ref005","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"K Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0357365.ref006","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"P DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"pone.0357365.ref007","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"MR Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0357365.ref008","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"I Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"10106","key":"pone.0357365.ref009","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"RL Coleman","year":"2017","journal-title":"Lancet"},{"issue":"34","key":"pone.0357365.ref010","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"BJ Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"pone.0357365.ref011","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"N McCabe","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"pone.0357365.ref012","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/cas.15477","article-title":"Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes","volume":"113","author":"H Onji","year":"2022","journal-title":"Cancer Sci"},{"key":"pone.0357365.ref013","doi-asserted-by":"crossref","first-page":"102803","DOI":"10.1016\/j.dnarep.2020.102803","article-title":"CRISPR\/CAS9-based DNA damage response screens reveal gene-drug interactions","volume":"87","author":"D Su","year":"2020","journal-title":"DNA Repair (Amst)"},{"issue":"12","key":"pone.0357365.ref014","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.1093\/nar\/gkae439","article-title":"The loss of DNA polymerase epsilon accessory subunits POLE3-POLE4 leads to BRCA1-independent PARP inhibitor sensitivity","volume":"52","author":"H Mamar","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"pone.0357365.ref015","doi-asserted-by":"crossref","first-page":"114205","DOI":"10.1016\/j.celrep.2024.114205","article-title":"Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors","volume":"43","author":"BR Hill","year":"2024","journal-title":"Cell Rep"},{"issue":"3","key":"pone.0357365.ref016","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41416-024-02749-w","article-title":"PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex","volume":"131","author":"L Qiu","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"pone.0357365.ref017","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1038\/s41467-023-42850-x","article-title":"Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51","volume":"14","author":"L Tao","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0357365.ref018","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1535-7163.MCT-23-0257","article-title":"SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma","volume":"23","author":"H Akashi","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"47","key":"pone.0357365.ref019","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"J Murai","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"pone.0357365.ref020","doi-asserted-by":"crossref","first-page":"102550","DOI":"10.1016\/j.jbc.2022.102550","article-title":"Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer","volume":"298","author":"O Deng","year":"2022","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0357365.ref021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41420-021-00638-2","article-title":"Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors","volume":"7","author":"J Xu","year":"2021","journal-title":"Cell Death Discov"},{"issue":"4","key":"pone.0357365.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095649","article-title":"Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer","volume":"9","author":"L Szabova","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"pone.0357365.ref023","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/cancers16040741","article-title":"Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1\/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient","volume":"16","author":"TG Meijer","year":"2024","journal-title":"Cancers (Basel)"},{"key":"pone.0357365.ref024","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55070","article-title":"Co-regulation and function of FOXM1\/RHNO1 bidirectional genes in cancer","volume":"10","author":"CJ Barger","year":"2021","journal-title":"Elife"},{"key":"pone.0357365.ref025","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1538-7445.AM2025-1872","article-title":"Abstract 1872: MSH6 modulates PARP inhibitor sensitivity in BRCA-proficient high-grade serous ovarian cancer","volume":"85","author":"O Deng","year":"2025","journal-title":"Cancer Research"},{"issue":"5","key":"pone.0357365.ref026","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors","volume":"51","author":"DJ Giard","year":"1973","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"pone.0357365.ref027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI114784","article-title":"Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells","volume":"86","author":"GB Mills","year":"1990","journal-title":"J Clin Invest"},{"issue":"4","key":"pone.0357365.ref028","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H","article-title":"Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines","volume":"28","author":"C Rauh-Adelmann","year":"2000","journal-title":"Mol Carcinog"},{"issue":"1","key":"pone.0357365.ref029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/gyno.1994.1090","article-title":"Glucocorticoids stabilize HER-2\/neu messenger RNA in human epithelial ovarian carcinoma cells","volume":"53","author":"BY Karlan","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"3","key":"pone.0357365.ref030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.2910450306","article-title":"Metallothionein gene expression and resistance to cisplatin in human ovarian cancer","volume":"45","author":"RJ Schilder","year":"1990","journal-title":"Int J Cancer"},{"issue":"4","key":"pone.0357365.ref031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0344-0338(99)80040-5","article-title":"Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture","volume":"195","author":"M Emoto","year":"1999","journal-title":"Pathol Res Pract"},{"issue":"9","key":"pone.0357365.ref032","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/nprot.2012.097","article-title":"Primary culture and immortalization of human fallopian tube secretory epithelial cells","volume":"7","author":"AM Karst","year":"2012","journal-title":"Nat Protoc"},{"issue":"1","key":"pone.0357365.ref033","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1038\/s41598-019-43154-1","article-title":"An Integrated Chemical Proteomics Approach for Quantitative Profiling of Intracellular ADP-Ribosylation","volume":"9","author":"K Kalesh","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0357365.ref034","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot087379","article-title":"Crystal violet assay for determining viability of cultured cells","volume":"2016","author":"M Feoktistova","year":"2016","journal-title":"Cold Spring Harb Protoc"},{"issue":"5","key":"pone.0357365.ref035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/1087057114521867","article-title":"A New Bliss Independence Model to Analyze Drug Combination Data","volume":"19","author":"W Zhao","year":"2014","journal-title":"J Biomol Screen"},{"issue":"8","key":"pone.0357365.ref036","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"NE Sanjana","year":"2014","journal-title":"Nat Methods"},{"issue":"12","key":"pone.0357365.ref037","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2016.10.011","article-title":"Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets","volume":"23","author":"CE Knezevic","year":"2016","journal-title":"Cell Chem Biol"},{"key":"pone.0357365.ref038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-61779-364-6_3","article-title":"Compound immobilization and drug-affinity chromatography","volume":"803","author":"U Rix","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"12","key":"pone.0357365.ref039","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"J Cox","year":"2008","journal-title":"Nat Biotechnol"},{"key":"pone.0357365.ref040","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Y Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"pone.0357365.ref041","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-14-153","article-title":"Iterative rank-order normalization of gene expression microarray data","volume":"14","author":"EA Welsh","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"pone.0357365.ref042","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Y Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"pone.0357365.ref043","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1113","article-title":"The STRING database in 2025: protein networks with directionality of regulation","volume":"53","author":"D Szklarczyk","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"pone.0357365.ref044","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cels.2023.07.007","article-title":"A proteogenomics data-driven knowledge base of human cancer","volume":"14","author":"Y Liao","year":"2023","journal-title":"Cell Syst"},{"issue":"7","key":"pone.0357365.ref045","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3390\/cancers12071939","article-title":"Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting","volume":"12","author":"A Bradbury","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"pone.0357365.ref046","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.chembiol.2021.07.008","article-title":"The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors","volume":"29","author":"V Palve","year":"2022","journal-title":"Cell Chem Biol"},{"issue":"6","key":"pone.0357365.ref047","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1073\/pnas.1106696109","article-title":"Interplay between mismatch repair and chromatin assembly","volume":"109","author":"B Sch\u00f6pf","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"pone.0357365.ref048","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0968-0004(00)89089-1","article-title":"Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks","volume":"20","author":"T Lindahl","year":"1995","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"pone.0357365.ref049","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2004.11.002","article-title":"NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1","volume":"119","author":"MY Kim","year":"2004","journal-title":"Cell"},{"issue":"3","key":"pone.0357365.ref050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/nar\/gkv1383","article-title":"Readers of poly(ADP-ribose): designed to be fit for purpose","volume":"44","author":"F Teloni","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"pone.0357365.ref051","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","article-title":"Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer","volume":"45","author":"B Gy\u0151rffy","year":"2023","journal-title":"Geroscience"},{"issue":"6","key":"pone.0357365.ref052","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Y Sancak","year":"2007","journal-title":"Mol Cell"},{"issue":"12","key":"pone.0357365.ref053","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/onc.2014.91","article-title":"Nuclear PRAS40 couples the Akt\/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway","volume":"34","author":"JJ Havel","year":"2015","journal-title":"Oncogene"},{"key":"pone.0357365.ref054","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2014.00163","article-title":"Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines","volume":"4","author":"BA Davidson","year":"2014","journal-title":"Front Oncol"},{"issue":"11","key":"pone.0357365.ref055","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.dnarep.2011.08.012","article-title":"PARP-1 enhances the mismatch-dependence of 5\u2019-directed excision in human mismatch repair in vitro","volume":"10","author":"Y Liu","year":"2011","journal-title":"DNA Repair (Amst)"},{"issue":"52","key":"pone.0357365.ref056","doi-asserted-by":"crossref","first-page":"40974","DOI":"10.1074\/jbc.M006520200","article-title":"Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins","volume":"275","author":"JM Pleschke","year":"2000","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0357365.ref057","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1101\/gad.10.4.407","article-title":"Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair","volume":"10","author":"GT Marsischky","year":"1996","journal-title":"Genes Dev"},{"issue":"21","key":"pone.0357365.ref058","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1038\/sj.onc.1207462","article-title":"The mismatch DNA repair heterodimer, hMSH2\/6, regulates BLM helicase","volume":"23","author":"Q Yang","year":"2004","journal-title":"Oncogene"},{"key":"pone.0357365.ref059","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.mad.2008.02.012","article-title":"DNA mismatch repair: molecular mechanism, cancer, and ageing","volume":"129","author":"P Hsieh","year":"2008","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"pone.0357365.ref060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2004.06.024","article-title":"Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility","volume":"6","author":"G Yang","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"pone.0357365.ref061","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4143\/crt.2021.828","article-title":"Frequency of mismatch repair deficiency\/high microsatellite instability and its role as a predictive biomarker of response to immune checkpoint inhibitors in gynecologic cancers","volume":"54","author":"JJ Noh","year":"2022","journal-title":"Cancer Res Treat"},{"key":"pone.0357365.ref062","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trsl.2023.05.004","article-title":"Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes","volume":"260","author":"N H\u00e1jkov\u00e1","year":"2023","journal-title":"Transl Res"},{"issue":"8","key":"pone.0357365.ref063","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ijc.25835","article-title":"Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America","volume":"129","author":"MA Murphy","year":"2011","journal-title":"Int J Cancer"},{"issue":"3","key":"pone.0357365.ref064","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ygyno.2019.12.031","article-title":"High homogeneity of MMR deficiency in ovarian cancer","volume":"156","author":"C Fraune","year":"2020","journal-title":"Gynecol Oncol"},{"key":"pone.0357365.ref065","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"I Cortes-Ciriano","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"pone.0357365.ref066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103988","article-title":"Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes","volume":"9","author":"CM Beaufort","year":"2014","journal-title":"PLoS One"},{"key":"pone.0357365.ref067","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1471-2407-6-201","article-title":"Mismatch repair and treatment resistance in ovarian cancer","volume":"6","author":"J Helleman","year":"2006","journal-title":"BMC Cancer"},{"issue":"3","key":"pone.0357365.ref068","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nbt.2121","article-title":"Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors","volume":"30","author":"E Wahlberg","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"8007","key":"pone.0357365.ref069","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"M Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"4","key":"pone.0357365.ref070","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1128\/MCB.20.4.1206-1218.2000","article-title":"A CAF-1-PCNA-mediated chromatin assembly pathway triggered by sensing DNA damage","volume":"20","author":"JG Moggs","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"1","key":"pone.0357365.ref071","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41419-025-07468-5","article-title":"Chromatin assembly factor 1 subunit A promotes TLS pathway by recruiting E3 ubiquitin ligase RAD18 in cancer cells","volume":"16","author":"B Wen","year":"2025","journal-title":"Cell Death Dis"},{"issue":"8","key":"pone.0357365.ref072","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.embor.7400750","article-title":"The replication kinase Cdc7-Dbf4 promotes the interaction of the p150 subunit of chromatin assembly factor 1 with proliferating cell nuclear antigen","volume":"7","author":"A G\u00e9rard","year":"2006","journal-title":"EMBO Rep"},{"issue":"3","key":"pone.0357365.ref073","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the Dependency of Cellular Protein Levels on mRNA Abundance","volume":"165","author":"Y Liu","year":"2016","journal-title":"Cell"},{"issue":"1","key":"pone.0357365.ref074","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.1038\/s41598-017-08502-z","article-title":"Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs","volume":"7","author":"M Zhang","year":"2017","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:35:21Z","timestamp":1788370521000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357365"}},"subtitle":[],"editor":[{"given":"Giovanni","family":"Nassa","sequence":"first","affiliation":[{"name":"University of Salerno","place":["ITALY"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357365","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}